Condition

Recurrent Squamous Cell Carcinoma of the Nasopharynx

ClinicalTrials.gov condition label

Clinical trials10

Recruiting0

Common interventions18

Lead sponsors shown3

Clinical trials

10 shown

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionNCT01249443 · 2013-11-01

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerNCT01528137 · 2012-05-01

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerNCT00397384 · 2007-01-01

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsNCT00089362 · 2004-07-01

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497 · 2003-08-01

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckNCT00063895 · 2003-04-01

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionNCT00030498 · 2001-12-01

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01

Common interventions

laboratory biomarker analysisOTHER6 erlotinib hydrochlorideDRUG4 pharmacological studyOTHER3 diagnostic laboratory biomarker analysisOTHER2 7-hydroxystaurosporineDRUG1 ABI-007/carboplatin/trastuzumabBIOLOGICAL1 alvespimycin hydrochlorideDRUG1 bevacizumabBIOLOGICAL1 carboplatinDRUG1 cetuximabBIOLOGICAL1 cetuximabDRUG1 gefitinibDRUG1 irinotecan hydrochlorideDRUG1 paclitaxelDRUG1 pharmacogenomic studiesOTHER1 recombinant interleukin-12BIOLOGICAL1 talactoferrinBIOLOGICAL1 vorinostatDRUG1

Leading sponsors

National Cancer Institute (NCI)8 AIDS Malignancy Consortium1 Stanford University1

Trial status mix

COMPLETED8

TERMINATED2

Phase mix

PHASE19

PHASE22

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.